CD34 and prostate cancer: Murine EML (erythroid, myeloid and lymphoid) is a BM‐derived multipotent hematopoietic cell line used to model HSPCs in vitro.[42] ORP100S was found to be more effective than rhTRX in promoting the proliferation of both EML cells and CD34‐positive human cord blood cells (CD34+)[43] but unlike rhTRX did not stimulate the proliferation of either hematological or solid tumor‐derived cancer cell lines (HT29 human colon cancer, MM1.R human myeloma, MV4‐11 human leukemia, B16‐F10 murine melanoma, EG7 murine lymphoma, and TRAMP murine prostate cancer) (Figure2A; Figure S3A, Supporting Information).